Little Green Pharma Valuation
Is LGP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of LGP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: LGP (A$0.13) is trading below our estimate of fair value (A$0.16)
Significantly Below Fair Value: LGP is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LGP?
Key metric: As LGP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is LGP's PS Ratio? | |
|---|---|
| PS Ratio | 1.6x |
| Sales | AU$25.63m |
| Market Cap | AU$40.74m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | -8.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does LGP's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.7x | ||
SPL Starpharma Holdings | 5.1x | n/a | AU$45.9m |
VIT Vitura Health | 0.5x | n/a | AU$54.1m |
CAN Cann Group | 1.2x | n/a | AU$21.6m |
PER Percheron Therapeutics | 27.9x | 45.3% | AU$85.9m |
LGP Little Green Pharma | 1.6x | 16.3% | AU$40.7m |
Price-To-Sales vs Peers: LGP is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (8.7x).
Price to Sales Ratio vs Industry
How does LGP's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?
| 17 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 5.5x | 33.0% | |
LGP Little Green Pharma | 1.6x | 16.3% | US$26.45m |
MYX Mayne Pharma Group | 1x | 11.3% | US$245.19m |
PBP Probiotec | 1.1x | 6.7% | US$160.13m |
| 17 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 5.5x | 43.7% | |
LGP Little Green Pharma | 1.6x | 110.1% | US$26.45m |
Price-To-Sales vs Industry: LGP is good value based on its Price-To-Sales Ratio (1.6x) compared to the Australian Pharmaceuticals industry average (5.5x).
Price to Sales Ratio vs Fair Ratio
What is LGP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.6x |
| Fair PS Ratio | 2.3x |
Price-To-Sales vs Fair Ratio: LGP is good value based on its Price-To-Sales Ratio (1.6x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
AVITA Medical
US$313.4m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.71
7D
4.8%
1Y
-2.4%
Medical Developments International
AU$48.4m
Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.
MVP
AU$0.42
7D
-3.4%
1Y
-44.4%
AVITA Medical
US$326.0m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.79
7D
3.0%
1Y
8.9%